2025-06-16-花旗集团-因塞特公司（INCY）_因塞特公司（INCY.O）_原发性血小板增多症的早期mCALR数据闪现同类首创希望_11页_360kb

Incyte Corporation (INCY.O) Report Summary

Clinical Data and Drug Performance

Incyte reported additional Phase 1 trial data for INCA033989, a first-in-class mutant CALR antibody for essential thrombocythemia (ET). At doses of 400mg and above, 82% of patients achieved a complete response (platelet counts <400,000/µL), with 89% showing a molecular response (reduction in peripheral blood mCALR variant allele frequency [VAF]). The drug was well-tolerated with no dose-limiting toxicities; AE profile includes fatigue, upper respiratory tract infections, and lipase increases (Grade 3 or worse in 6% of patients, but asymptomatic and resolved). Experts highlighted impressive normalization of platelet counts and potential disease-modifying effects. MF data expected later in 2H25.

Tolerability and Partner Collaboration

INCA033989 was well-tolerated across all dose cohorts; only one patient discontinued treatment, and side effects were generally mild (Grades 1-2). A partnership with QIAGEN supports development of a diagnostic panel for myeloproliferative neoplasms to aid therapeutic decision-making via next-generation sequencing technology.

Valuation and Risk Assessment

Citi assigned a "Buy" rating with High Risk, based on DCF analysis projecting a target price of $88, anticipated total return of 29.9%, and market cap of $13.1B. Risks include biotech stock volatility, commercial revenue uncertainties, clinical/regulatory hurdles, and competition from drugs like Jakafi and Opzelura.